Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Nike Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Nike Inc trades at $35.43 (market cap $52.48B). The key difference: Nike Inc is far larger — about 53.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Nike Inc pays a 4.64% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Nike Inc for 155 Days on average.
| MRVI | NKE | |
|---|---|---|
Market Cap | $972.90M | $52.48B |
Volume | 4,325,710 | 30,189,626 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $69.68 |
52-Week Low | $2.83 | $33.87 |
Typical Hold Time | 0 Days | 155 Days |
Enterprise Value | $1.08B | $55.18B |
Dividend Yield | — | 4.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NKE trades at $35.33, down slightly (-0.06%) on the day, with a bearish technical signal. The stock has a P/E of 16.9 and P/S of 1.14, trading below the analyst consensus price target of $36.80. Recent earnings have consistently beaten expectations, but revenue and net income have declined year-over-year. The company maintains strong brand equity but faces headwinds in key markets like China.
NKE's investment case hinges on its brand strength and potential for a turnaround, but near-term risks include sluggish consumer demand and margin pressure. The stock offers a dividend yield, but investors should weigh the execution risks of its strategic initiatives against its current valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
